Literature DB >> 2066986

Functionalized congener approach to muscarinic antagonists: analogues of pirenzepine.

Y Karton1, B J Bradbury, J Baumgold, R Paek, K A Jacobson.   

Abstract

The M1-selective muscarinic receptor antagonist pirenzepine 6H-pyrido[2,3-b][1,4]benzodiazepin-6-one) was derivatized to explore points of attachment of functionalized side chains for the synthesis of receptor probes and ligands for affinity chromatography. The analogues prepared were evaluated in competitive binding assays versus [3H]-N-methylscopolamine at four muscarinic receptor subtypes (m1AChR-m4AChR) in membranes from rat heart tissue and transfected A9L cells. 9-(Hydroxymethyl)pirenzepine, 8-(methylthio)pirenzepine, and a series of 8-aminosulfonyl derivatives were synthesized. Several 5-substituted analogues of pirenzepine also were prepared. An alternate series of analogues substituted on the 4-position of the piperazine ring was prepared by reaction of 4-desmethylpirenzepine with various electrophiles. An N-chloroethyl analogue of pirenzepine was shown to form a reactive aziridine species in aqueous buffer yet failed to affinity label muscarinic receptors. Within a series of aminoalkyl analogues, the affinity increased as the length of the alkyl chain increased. Shorter chain analogues were generally much less potent than pirenzepine, and longer analogues (7-10 carbons) were roughly as potent as pirenzepine at m1 receptors, but were nonselective. Depending on the methylene chain length, acylation or alkyl substitution of the terminal amine also influenced the affinity at muscarinic receptors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2066986      PMCID: PMC3469255          DOI: 10.1021/jm00111a032

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  29 in total

1.  Aprophit: an irreversible antagonist for muscarinic receptors.

Authors:  A H Newman; J Covington; M Oleshansky; B W Jackson; B A Weissman; H Leader; P K Chiang
Journal:  Biochem Pharmacol       Date:  1990-09-15       Impact factor: 5.858

Review 2.  Muscarinic receptor subtypes. Physiology and clinical implications.

Authors:  R K Goyal
Journal:  N Engl J Med       Date:  1989-10-12       Impact factor: 91.245

Review 3.  Muscarinic pharmacology of the airways.

Authors:  J Maclagan; P J Barnes
Journal:  Trends Pharmacol Sci       Date:  1989-12       Impact factor: 14.819

4.  Functionalized congener approach for the design of novel muscarinic agents. Synthesis and pharmacological evaluation of N-methyl-N-[4-(1-pyrrolidinyl)-2-butynyl] amides.

Authors:  B J Bradbury; J Baumgold; K A Jacobson
Journal:  J Med Chem       Date:  1990-02       Impact factor: 7.446

5.  Muscarinic receptor binding and activation of second messengers by substituted N-methyl-N-[4-(1-azacycloalkyl)-2-butynyl]acetamides.

Authors:  B J Bradbury; J Baumgold; R Paek; U Kammula; J Zimmet; K A Jacobson
Journal:  J Med Chem       Date:  1991-03       Impact factor: 7.446

6.  Tertiary 2-haloethylamine derivatives of the muscarinic agent McN-A-343, [4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium chloride.

Authors:  B Ringdahl; C Mellin; F J Ehlert; M Roch; K M Rice; D J Jenden
Journal:  J Med Chem       Date:  1990-01       Impact factor: 7.446

7.  Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes.

Authors:  T I Bonner; A C Young; M R Brann; N J Buckley
Journal:  Neuron       Date:  1988-07       Impact factor: 17.173

8.  Pirenzepine distinguishes between different subclasses of muscarinic receptors.

Authors:  R Hammer; C P Berrie; N J Birdsall; A S Burgen; E C Hulme
Journal:  Nature       Date:  1980-01-03       Impact factor: 49.962

Review 9.  Structure-activity relationships and pharmacological profile of selective tricyclic antimuscarinics.

Authors:  W G Eberlein; W Engel; G Mihm; K Rudolf; B Wetzel; M Entzeroth; N Mayer; H N Doods
Journal:  Trends Pharmacol Sci       Date:  1989-12       Impact factor: 14.819

10.  Purification and characterization of bovine cerebral cortex A1 adenosine receptor.

Authors:  M E Olah; K A Jacobson; G L Stiles
Journal:  Arch Biochem Biophys       Date:  1990-12       Impact factor: 4.013

View more
  5 in total

Review 1.  Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs).

Authors:  Kenneth A Jacobson
Journal:  Bioconjug Chem       Date:  2009-04-30       Impact factor: 4.774

Review 2.  Molecular probes for muscarinic receptors: functionalized congeners of selective muscarinic antagonists.

Authors:  K A Jacobson; B Fischer; A M van Rhee
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

3.  High affinity acylating antagonists for muscarinic receptors.

Authors:  J Baumgold; Y Karton; N Malka; K A Jacobson
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

4.  Unexpected scaffold rearrangement product of pirenzepine found in commercial samples.

Authors:  Marius Ozenil; Lukas Skos; Alexander Roller; Natalie Gajic; Wolfgang Holzer; Helmut Spreitzer; Sonja Platzer-Ozenil; Chrysoula Vraka; Marcus Hacker; Wolfgang Wadsak; Verena Pichler
Journal:  Sci Rep       Date:  2021-12-03       Impact factor: 4.379

5.  Molecular probes for muscarinic receptors: derivatives of the M1-antagonist telenzepine.

Authors:  Y Karton; J Baumgold; J S Handen; K A Jacobson
Journal:  Bioconjug Chem       Date:  1992 May-Jun       Impact factor: 4.774

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.